These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 10963494

  • 1. Undetectable prostate-specific antigen response with bicalutamide withdrawal phenomenon.
    El-Gabry EA, Strup SE, Gomella LG.
    Tech Urol; 2000 Sep; 6(3):221-2. PubMed ID: 10963494
    [Abstract] [Full Text] [Related]

  • 2. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.
    Schellhammer PF, Venner P, Haas GP, Small EJ, Nieh PT, Seabaugh DR, Patterson AL, Klein E, Wajsman Z, Furr B, Chen Y, Kolvenbag GJ.
    J Urol; 1997 May; 157(5):1731-5. PubMed ID: 9112515
    [Abstract] [Full Text] [Related]

  • 3. A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.
    Lau YK, Chadha MK, Litwin A, Trump DL.
    J Hematol Oncol; 2008 Nov 05; 1():21. PubMed ID: 18986533
    [Abstract] [Full Text] [Related]

  • 4. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T, Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group.
    J Urol; 2008 Sep 05; 180(3):921-7. PubMed ID: 18635218
    [Abstract] [Full Text] [Related]

  • 5. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
    Sartor O, Gomella LG, Gagnier P, Melich K, Dann R.
    Can J Urol; 2009 Oct 05; 16(5):4806-12. PubMed ID: 19796455
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Phase I-II trial of weekly bicalutamide in men with elevated prostate-specific antigen and negative prostate biopsies.
    Zanardi S, Puntoni M, Maffezzini M, Bandelloni R, Mori M, Argusti A, Campodonico F, Turbino L, Branchi D, Montironi R, Decensi A.
    Cancer Prev Res (Phila); 2009 Apr 05; 2(4):377-84. PubMed ID: 19336728
    [Abstract] [Full Text] [Related]

  • 11. [Intermittent androgen deprivation treatment of prostate cancer restarted at low level of serum prostate specific antigen: a pilot study].
    Maekawa S, Maegawa M, Ushida H, Inoue K, Kaneko Y, Ohmori K, Nishimura K.
    Hinyokika Kiyo; 2001 Aug 05; 47(8):553-5. PubMed ID: 11579594
    [Abstract] [Full Text] [Related]

  • 12. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K, Arichi N, Tokugawa S, Yoshioka I, Kishikawa H, Ichikawa Y.
    Int J Urol; 2007 Mar 05; 14(3):264-7. PubMed ID: 17430272
    [Abstract] [Full Text] [Related]

  • 13. An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study.
    Klotz L, Drachenberg D, Singal R, Aprikian A, Fradet Y, Kebabdjian M, Zarenda M, Chin J.
    Prostate Cancer Prostatic Dis; 2014 Dec 05; 17(4):320-4. PubMed ID: 25179591
    [Abstract] [Full Text] [Related]

  • 14. [Reevaluation of MAB therapy and progress of endocrine therapy].
    Klotz L, Payne H, Gillatt D, Keane T, Morris C, Akaza H, Hirao, Akakura K, Fukagai T.
    Gan To Kagaku Ryoho; 2005 May 05; 32(5):705-28. PubMed ID: 15934164
    [No Abstract] [Full Text] [Related]

  • 15. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N, Onishi T, Arima K, Sugimura Y.
    Int J Urol; 2007 Mar 05; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
    Davis NB, Ryan CW, Stadler WM, Vogelzang NJ.
    BJU Int; 2005 Oct 05; 96(6):787-90. PubMed ID: 16153201
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
    Sakai H, Igawa T, Tsurusaki T, Yura M, Kusaba Y, Hayashi M, Iwasaki S, Hakariya H, Hara T, Kanetake H.
    Urology; 2009 Mar 05; 73(3):635-40. PubMed ID: 19038426
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.